Extended Data Fig. 4: SDC1 is required for tumorigenic activity of KRAS*-driven PDAC. | Nature

Extended Data Fig. 4: SDC1 is required for tumorigenic activity of KRAS*-driven PDAC.

From: Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer

Extended Data Fig. 4: SDC1 is required for tumorigenic activity of KRAS*-driven PDAC.The alternative text for this image may have been generated using AI.

a, Representative images of clonogenic assay for two independent iKras* p53L/+ PDAC cells infected with scrambled shRNA or shRNA against Sdc1. Experiments were repeated three times with similar results. b, c, Validation of Sdc1 knockdown by RT–qPCR (b) and FACS analysis with anti-SDC1 antibody (c) in iKras* p53L/+ PDAC cells infected with scrambled shRNA or shRNA against Sdc1. In b, n = 3; data are mean ± s.d.; P values were determined by unpaired two-sided Student’s t-test. In c, experiments were repeated three times with similar results. d, Two independent iKras* p53L/+ tumour cells stably expressing SDC1 or empty vector were infected with scrambled shRNA or shRNA against Sdc1. Quantification of clonogenic assay is shown (n = 4 biological replicates; data are mean ± s.d.). P values were determined by unpaired two-sided Student’s t-test. e, Digital photographs of dissected tumours from mice implanted with iKras* p53L/+ tumour cells containing scrambled shRNA or shRNA against Sdc1. f, Validation of double nickase-mediated Sdc1 deletion in iKras* p53L/+ PDAC cells using 281-2 anti-SDC1 antibody and FACS analysis. Experiments were repeated twice with similar results. g, Representative figure of clonogenic assay for iKras* p53L/+ PDAC cells with wild-type SDC1 or double nickase-mediated Sdc1 deletion. Experiments were repeated twice with similar results. h, Digital photographs of dissected tumours from mice implanted with iKras* p53L/+ tumour cells with wild-type SDC1 or double nickase-mediated Sdc1 deletion. i, Representative figure of clonogenic assay for human PDAC cells infected with scrambled shRNA or shRNA against SDC1. Experiments were repeated twice with similar results. j, Validation of SDC1 knockdown by shRNA in human PDAC cell lines from (i) using DL-101 anti-SDC1 antibody and FACS analysis. Experiments were repeated twice with similar results. k, Digital photographs of dissected tumours from subcutaneous xenografts of mice implanted with PATC69 cells infected with scrambled shRNA or shRNA against SDC1.

Source data

Back to article page